id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-281871-3j64de2i	Sinagra, G	Viral presence guided immunomodulation in lymphocytic myocarditis: An update	2020-07-19		.txt	text/plain	2743	143	32	In patients with lymphocytic myocarditis and heart failure (HF) with severe left ventricular dysfunction or lifethreatening ventricular arrhythmias who do not respond to conventional treatments in the short term (i.e. 7-10 days), EMB may guide more advanced medical therapy, including immunosuppression and immunomodulation 1 state, "Immunosuppression should be started only after ruling out active infection on EMB by PCR," and, "Immunosuppression may be considered, on an individual basis, in infection-negative lymphocytic myocarditis refractory to standard therapy in patients with no contraindications to Accepted Article immunosuppression." 4 Accordingly, the latest version of the Cochrane bank analysis 5 reports, "Corticosteroids may have a role in treating myocarditis without viral evidence." The same recommendations have been reaffirmed in recent reviews 1, 6, 7 , where different international experts highlight the need for ruling out viral presence in EMB via PCR analysis before starting immunosuppression or immunomodulation in clinically suspected acute myocarditis patients presenting life-threatening scenarios.	./cache/cord-281871-3j64de2i.txt	./txt/cord-281871-3j64de2i.txt